Pre-earnings brief
Reports
Thu, Dec 1, 2022
Est. EPS
—
Est. revenue
—
Implied move
±5.0%
EPS beat rate
67%
Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. Operating in the health care sector, it plays a crucial role in advancing medical science and improving patient outcomes.
Last quarter
In the last quarter, Legend Biotech reported an EPS of -0.16, which was better than the estimated -0.29, resulting in a positive surprise. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.
EPS beat streak
1Q
EPS beat rate
67%
Avg EPS surprise
+12.73%
Avg 1-day reaction
+3.44%
Investors are cautiously optimistic ahead of the earnings report, given the company's history of beating EPS estimates. However, the lack of revenue guidance raises concerns about future growth.
Bull case
If Legend Biotech continues its trend of beating EPS estimates, it could signal strong operational efficiency and potentially lead to a positive stock reaction.
Bear case
Conversely, if the company fails to provide clear revenue guidance or reports a significant loss, it could lead to a negative market reaction.
The print will turn on these.
Q1
What will the EPS figure be this quarter?
The EPS result will be closely watched as it can significantly affect investor sentiment and stock performance.
Q2
Will there be any guidance on revenue growth?
Clear revenue guidance is crucial for understanding the company's growth trajectory and market position.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The Street may underestimate the potential for Legend Biotech to exceed EPS expectations due to its recent operational improvements.
Supporting evidence
The company has a 67% EPS beat rate historically, indicating a strong track record.
Options pricing suggests a relatively low expected move, which may not fully capture the company's potential for surprise.
Key risk
If the EPS comes in better than expected, it could shift market sentiment significantly.
Pre-commit to what would confirm each case.
The market is debating whether Legend Biotech can maintain its positive EPS trend while providing solid revenue growth.
Bull confirmed if
A positive EPS surprise of more than 20% would support the bullish case.
Bear confirmed if
An EPS loss greater than -0.30 would confirm the bearish outlook.
What the market is pricing for the move.
Implied Move
±5%
Historical Avg
±6.1%
The options market is pricing in a 5% move in either direction, indicating uncertainty about the upcoming earnings report.
Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.
30d HV
72.4%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$258,920.20
27,370 sh
1 insider
Net
$258,920.20
Net selling
Most Active Insiders· 1 open-market trade
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71%, confirming operational strength.
In line / cautious
If results are in line but lack clarity on future guidance, the stock may see muted movement as investors reassess their outlook.
Miss
A miss on EPS could lead to a decline of approximately 6.91%, reflecting investor disappointment.
The lines on the call that would change the story.
$258,920.20
Net selling
Recent Transactions
Sep 29, 2026 · @ $9.46
27,370 sh
$258,920.20
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.